• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Genmab Publishes 2024 Annual Report

    2/12/25 11:01:37 AM ET
    $GMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $GMAB alert in real time by email

    Company Announcement

    COPENHAGEN, Denmark; February 12, 2025 – Genmab A/S (NASDAQ:GMAB) announced today the publication of its Annual Report for 2024. Below is a summary of business progress in 2024, financial performance for the year and the financial outlook for 2025. The full report is attached as a PDF file and in iXBRL format and can be found in the investor section of the company's website, www.genmab.com/investor-relations.

    Conference Call

    Genmab will hold a conference call to discuss the full year results for 2024 today, February 12, 2025, at 6:00 pm CET, 5:00 pm GMT, 12:00 pm EST. To join the call please use the below registration link. Registered participants will receive an email with a link to access dial-in information as well as a unique personal PIN: https://register.vevent.com/register/BI5982e6aa32af485f851860da1a450df3.

    A live and archived webcast of the call and relevant slides will be available at www.genmab.com/investor-relations.

    2024 ACHIEVEMENTS



    Business Progress

    • EPKINLY®/TEPKINLY® (epcoritamab) became the first and only subcutaneous (SC) bispecific antibody approved in both the U.S. and Europe to treat both relapsed or refractory follicular lymphoma (FL) and relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy
    • Acquisition of ProfoundBio Inc. (ProfoundBio), granting Genmab worldwide rights to multiple candidates in development (including rinatabart sesutecan (Rina-S™)) plus ProfoundBio's novel antibody-drug conjugate (ADC) technology platforms
    • Genmab submitted a supplemental Japan New Drug Application (J-NDA) to the Ministry of Health, Labour and Welfare (MHLW) for SC EPKINLY for the treatment of relapsed or refractory FL after two or more lines of systemic therapy
    • Tivdak® (tisotumab vedotin-tftv) received full U.S. Food and Drug Administration (U.S. FDA) approval to treat recurrent or metastatic cervical cancer
    • Genmab submitted a J-NDA to the MHLW for Tivdak for the treatment of advanced or recurrent cervical cancer
    • Genmab assumed sole responsibility for the continued development and potential commercialization of acasunlimab
    • Two Genmab wholly owned programs, Rina-S and acasunlimab, moved into Phase 3 development
    • Multiple programs entered clinical-stage development including GEN1059 (BNT314, DuoBody®-EpCAMx4-1BB), GEN1055 (BNT315, HexaBody®-OX40), GEN1057 (DuoBody-FAPαxDR4) and GEN1286 (EGFRxcMET ADC)
    • Additional regulatory approvals for J&J therapies DARZALEX FASPRO® (daratumumab and hyaluronidase fihj) and RYBREVANT® (amivantamab)
    • Approval of Amgen's TEPEZZA® (teprotumumab) in Japan for the treatment of active thyroid eye disease
    • Continued development of Genmab's broader organizational infrastructure with the addition of over 600 new colleagues



    Financial Performance

    • Net sales of DARZALEX® by J&J were USD 11,670 million in 2024 compared to USD 9,744 million in 2023. The increase of USD 1,926 million, or 20%, was driven by share gains in all regions.
    • Global net sales of EPKINLY/TEPKINLY were USD 281 million in 2024. Net product sales in the U.S. and Japan by Genmab were DKK 1,743 million in 2024 compared to DKK 421 million in 2023. EPKINLY was approved in the U.S. in May 2023 and in Japan in September 2023.
    • Royalty revenue amounted to DKK 17,352 million in 2024 compared to DKK 13,705 million in 2023. The increase of DKK 3,647 million, or 27%, was primarily driven by higher DARZALEX and Kesimpta® (ofatumumab) royalties achieved under our daratumumab collaboration with J&J and ofatumumab collaboration with Novartis, respectively.
    • Genmab's revenue was DKK 21,526 million in 2024 compared to DKK 16,474 million in 2023. The increase of DKK 5,052 million, or 31%, was primarily driven by higher DARZALEX and Kesimpta royalties achieved under our collaborations with J&J and Novartis, respectively. Increased EPKINLY net product sales, driven by a strong product launch in 2023 with a full year of net sales in 2024, also contributed to increased revenue in 2024.
    • Genmab's operating expenses, including acquisition and integration charges related to ProfoundBio, were DKK 13,838 million, compared to DKK 10,927 million in 2023. In addition to the acquisition of ProfoundBio, this increase was driven by the increased and accelerated advancement of epcoritamab under our collaboration with AbbVie, the addition of ProfoundBio related research and development expenses, primarily Rina-S, advancement of acasunlimab and DuoBody-CD40x4-1BB under our collaboration with BioNTech SE (BioNTech), further progression of pipeline products, EPKINLY launch in the U.S. and Japan, the continued development of Genmab's broader organizational capabilities, and related increase in team members to support these activities.
    • Operating profit was DKK 6,703 million in 2024 compared to DKK 5,321 million in 2023, an increase of DKK 1,382 million, or 26%.

    2025 OUTLOOK

    (USD millions)2024 Actual Result2025 Guidance2025 Guidance Mid-Point2024 Growth %2025 Growth %*
    Revenue3,1243,340 - 3,6603,50031%12%
    Royalties2,5182,785 - 3,0152,90027%15%
    Net product sales/Collaboration revenue**316415 - 460438199%39%
    Milestones/Reimbursement revenue290140 - 185162-2%-44%
    Gross profit2,9813,120 - 3,4203,27026%10%
    Operating expenses(2,008)(2,055) - (2,225)(2,140)27%7%
    Operating profit973895 - 1,3651,13026%16%

    *Mid-point of guidance range

    **Net product sales and collaboration revenue consists of EPKINLY net product sales in the U.S. and Japan, and Tivdak (Genmab's share of gross profits).

    Revenue

    Genmab expects its 2025 revenue to be in the range of USD 3.3 – 3.7 billion, compared to USD 3.1 billion in 2024.

    Genmab's projected revenue growth for 2025 is driven by higher royalties, net product sales and collaboration revenue. Royalty growth relates mainly to DARZALEX and Kesimpta net sales growth. Net product sales and collaboration revenue growth is driven by strong performance for both EPKINLY and Tivdak. Net product sales and collaboration revenue consists of EPKINLY net product sales in the U.S. and Japan, and Tivdak (50% gross profit share).

    Genmab's projected revenue for 2025 primarily consists of DARZALEX royalties of approximately USD 2.2 billion at the midpoint. Such royalties are based on estimated DARZALEX 2025 net sales of USD 12.6 – 13.4 billion compared to actual net sales in 2024 of USD 11.7 billion. DARZALEX royalties are partly offset by Genmab's share of J&J's royalty payments to Halozyme Therapeutics, Inc. (Halozyme) in connection with SC net sales as well as royalty reduction in countries and territories where there is no Genmab patent coverage.

    The remainder of Genmab's revenue consists of royalties from Kesimpta, TEPEZZA, RYBREVANT, TECVAYLI®, TALVEY® and TEPKINLY, net product sales and collaboration revenue from EPKINLY and Tivdak, reimbursement revenue and milestones.

    Operating Expenses

    Genmab anticipates its 2025 operating expenses to be in the range of USD 2.1 – 2.2 billion, compared to USD 2.0 billion in 2024. The increase in operating expenses is primarily related to investments in late-stage programs and launch readiness in key markets.

    Operating Profit

    Genmab expects its 2025 operating profit to be in the range of USD 0.9 – 1.4 billion, compared to USD ~1.0 billion

    More information on the Risks and Assumptions for the 2025 Financial Guidance can be found in the 2024 Annual Report available on our website www.genmab.com/investor-relations.

    About Genmab

    Genmab is an international biotechnology company with a core purpose of guiding its unstoppable team to strive toward improving the lives of patients with innovative and differentiated antibody therapeutics. For more than 25 years, its passionate, innovative and collaborative team has invented next-generation antibody technology platforms and leveraged translational, quantitative and data sciences, resulting in a proprietary pipeline including bispecific T-cell engagers, antibody-drug conjugates, next-generation immune checkpoint modulators and effector function-enhanced antibodies. By 2030, Genmab's vision is to transform the lives of people with cancer and other serious diseases with knock-your-socks-off (KYSO) antibody medicines®.

     

    Established in 1999, Genmab is headquartered in Copenhagen, Denmark, with international presence across North America, Europe and Asia Pacific. For more information, please visit Genmab.com and follow us on LinkedIn and X.



    Contact:        

    Marisol Peron, Senior Vice President, Global Communications & Corporate Affairs

    T: +1 609 524 0065; E: [email protected]

    Andrew Carlsen, Vice President, Head of Investor Relations

    T: +45 3377 9558; E: [email protected]



    The Annual Report contains forward looking statements. The words "believe", "expect", "anticipate", "intend" and "plan" and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with pre-clinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products or technologies obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab's most recent financial reports, which are available on www.genmab.com and the risk factors included in Genmab's most recent Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission (SEC), which are available at www.sec.gov. Genmab does not undertake any obligation to update or revise forward looking statements in the Annual Report nor to confirm such statements to reflect subsequent events or circumstances after the date made or in relation to actual results, unless required by law.



    Genmab A/S and/or its subsidiaries own the following trademarks: Genmab®; the Y-shaped Genmab logo®; Genmab in combination with the Y-shaped Genmab logo®; HuMax®; DuoBody®; DuoBody in combination with the DuoBody logo®; HexaBody®; HexaBody in combination with the HexaBody logo®; DuoHexaBody®, HexElect® and KYSO®. Tivdak® is a trademark of Seagen Inc.; Kesimpta® and Sensoready® are trademarks of Novartis AG or its affiliates; DARZALEX®, DARZALEX FASPRO®, RYBREVANT®, TECVAYLI® and TALVEY™ are trademarks of Johnson & Johnson; EPKINLY®, TEPKINLY® and their designs are trademarks of AbbVie Biotechnology Ltd.; TEPEZZA® is a trademark of Horizon Therapeutics Ireland DAC. ©2025, Genmab A/S. All rights reserved.

    CVR no. 2102 3884

    LEI Code 529900MTJPDPE4MHJ122

    Genmab A/S

    Carl Jacobsens Vej 30

    2500 Valby

    Denmark

    Attachments

    • 120225_CA03_Genmab_2024_Annual_Report
    • Genmab-2024-12-31-0-en


    Primary Logo

    Get the next $GMAB alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $GMAB

    DatePrice TargetRatingAnalyst
    4/1/2025Mkt Perform → Underperform
    Bernstein
    3/11/2025Mkt Perform → Outperform
    William Blair
    2/13/2025$27.00Market Perform → Outperform
    Leerink Partners
    10/8/2024Buy
    Redburn Atlantic
    9/4/2024$31.00Equal-Weight
    Morgan Stanley
    8/20/2024Overweight → Neutral
    JP Morgan
    7/15/2024Sector Perform → Outperform
    RBC Capital Mkts
    2/23/2024$46.00 → $48.00Market Perform → Outperform
    BMO Capital Markets
    More analyst ratings

    $GMAB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Genmab A/S (Amendment)

      SC 13G/A - GENMAB A/S (0001434265) (Subject)

      2/8/24 10:03:08 AM ET
      $GMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Genmab A/S (Amendment)

      SC 13G/A - GENMAB A/S (0001434265) (Subject)

      2/2/24 2:18:06 PM ET
      $GMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Genmab A/S

      SC 13G - GENMAB A/S (0001434265) (Subject)

      2/6/23 2:36:15 PM ET
      $GMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GMAB
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Genmab to Submit Supplemental Biologics License Application (sBLA) to U.S. Food and Drug Administration for Epcoritamab Plus Rituximab and Lenalidomide (R2) in Patients with Relapsed/Refractory Follicular Lymphoma (FL)

      Decision to submit based on a positive overall response rate (ORR) (p-value < 0.0001), one of the dual primary endpoints in the Phase 3 EPCORE® FL-1 trial Full results from the trial will be submitted for presentation at an upcoming medical conference in 2025 Genmab A/S (NASDAQ:GMAB) announced today its intention to submit in the first half of 2025 a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) for subcutaneous epcoritamab, a bispecific antibody being investigated in combination with rituximab and lenalidomide (R2) for the treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma (FL), following at least one pr

      5/1/25 8:24:00 PM ET
      $GMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Genmab to Submit Supplemental Biologics License Application (sBLA) to U.S. Food and Drug Administration for Epcoritamab Plus Rituximab and Lenalidomide (R2) in Patients with Relapsed/Refractory Follicular Lymphoma (FL)

      Company Announcement Decision to submit based on a positive overall response rate (ORR) (p-value < 0.0001), one of the dual primary endpoints in the Phase 3 EPCORE® FL-1 trialFull results from the trial will be submitted for presentation at an upcoming medical conference in 2025 COPENHAGEN, Denmark; May 2, 2024 – Genmab A/S (NASDAQ:GMAB) announced today its intention to submit in the first half of 2025 a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) for subcutaneous epcoritamab, a bispecific antibody being investigated in combination with rituximab and lenalidomide (R2) for the treatment of adult patients with relapsed or refractory (R/R

      5/1/25 8:14:12 PM ET
      $GMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2025

      Company Announcement Net sales of DARZALEX® in the first quarter of 2025 totaled USD 3,237 millionGenmab receives royalties on worldwide net sales from Johnson & Johnson (J&J, legal entity Janssen Biotech, Inc.) COPENHAGEN, Denmark; April 15, 2025 – Genmab A/S (NASDAQ:GMAB) announced today that worldwide net trade sales of DARZALEX (daratumumab), including sales of the subcutaneous (SC) product (daratumumab and hyaluronidase-fihj, sold under the tradename DARZALEX FASPRO® in the U.S.), as reported by J&J were USD 3,237 million in the first quarter of 2025. Net trade sales were USD 1,829 million in the U.S. and USD 1,409 million in the rest of the world. Genmab receives royalties on the wo

      4/15/25 6:21:58 AM ET
      $GMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GMAB
    Leadership Updates

    Live Leadership Updates

    See more
    • Genmab Announces Appointment of Tahamtan Ahmadi to Newly Created Position of Chief Medical Officer, Head of Experimental Medicines

      Company Announcement COPENHAGEN, Denmark; February 22, 2021 – Genmab A/S (Nasdaq: GMAB) announced today that Tahamtan Ahmadi, M.D., Ph.D., has been appointed to the newly created position of Executive Vice President and Chief Medical Officer, Head of Experimental Medicines effective March 1, 2021. Dr. Tahi Ahmadi joined Genmab in 2017 and previously served as Genmab’s Senior Vice President, Head of Oncology. In this new role, Dr. Ahmadi will lead research, discovery, regulatory and medical activities. He joins the Executive Management Team of Chief Executive Officer Dr. Jan van de Winkel, Chief Development Officer Dr. Judith Klimovsky, Chief Financial Officer Anthony Pagano, and Chief Opera

      2/22/21 8:00:51 AM ET
      $GMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GMAB
    SEC Filings

    See more
    • SEC Form 6-K filed by Genmab A/S

      6-K - GENMAB A/S (0001434265) (Filer)

      5/8/25 11:19:36 AM ET
      $GMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Genmab A/S

      6-K - GENMAB A/S (0001434265) (Filer)

      5/5/25 11:05:13 AM ET
      $GMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Genmab A/S

      6-K - GENMAB A/S (0001434265) (Filer)

      5/1/25 8:21:13 PM ET
      $GMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GMAB
    Financials

    Live finance-specific insights

    See more
    • Genmab Announces Johnson & Johnson Decision Regarding HexaBody®-CD38

      Johnson & Johnson has decided that it will not exercise its option to receive a worldwide license to develop, manufacture and commercialize HexaBody-CD38 Genmab will not pursue further clinical development of HexaBody-CD38 Data validates clinical potential of the HexaBody platform Genmab to host a conference call today at 5:00 PM CET / 4:00 PM GMT / 12:00 PM EDT Genmab A/S (NASDAQ:GMAB) announced today that Johnson & Johnson (J&J) has decided that it will not exercise its option to receive a worldwide license to develop, manufacture and commercialize HexaBody-CD38 (GEN3014). While the initial HexaBody-CD38 clinical data is promising and showed robust clinical efficacy, following a

      3/10/25 10:21:00 AM ET
      $GMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Genmab Announces Johnson & Johnson Decision Regarding HexaBody®-CD38

      Company Announcement Johnson & Johnson has decided that it will not exercise its option to receive a worldwide license to develop, manufacture and commercialize HexaBody-CD38 Genmab will not pursue further clinical development of HexaBody-CD38Data validates clinical potential of the HexaBody platform Genmab to host a conference call today at 5:00 PM CET / 4:00 PM GMT / 12:00 PM EDT COPENHAGEN, Denmark; March 10, 2025 – Genmab A/S (NASDAQ:GMAB) announced today that Johnson & Johnson (J&J) has decided that it will not exercise its option to receive a worldwide license to develop, manufacture and commercialize HexaBody-CD38 (GEN3014). While the initial HexaBody-CD38 clinical data is promising

      3/10/25 10:13:07 AM ET
      $GMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Genmab Publishes 2024 Annual Report

      Company Announcement COPENHAGEN, Denmark; February 12, 2025 – Genmab A/S (NASDAQ:GMAB) announced today the publication of its Annual Report for 2024. Below is a summary of business progress in 2024, financial performance for the year and the financial outlook for 2025. The full report is attached as a PDF file and in iXBRL format and can be found in the investor section of the company's website, www.genmab.com/investor-relations. Conference CallGenmab will hold a conference call to discuss the full year results for 2024 today, February 12, 2025, at 6:00 pm CET, 5:00 pm GMT, 12:00 pm EST. To join the call please use the below registration link. Registered participants will receive an email

      2/12/25 11:01:37 AM ET
      $GMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GMAB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Genmab downgraded by Bernstein

      Bernstein downgraded Genmab from Mkt Perform to Underperform

      4/1/25 9:01:35 AM ET
      $GMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Genmab upgraded by William Blair

      William Blair upgraded Genmab from Mkt Perform to Outperform

      3/11/25 7:35:51 AM ET
      $GMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Genmab upgraded by Leerink Partners with a new price target

      Leerink Partners upgraded Genmab from Market Perform to Outperform and set a new price target of $27.00

      2/13/25 7:09:15 AM ET
      $GMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care